Teri LoxamChief Financial Officer at SQZ Biotechnologies
Teri is an accomplished professional with a diverse background in Investor Relations, Strategy, Communications and Finance. As SQZ’s Chief Financial Officer, Teri oversees the company’s financial operations including financial strategy, accounting, financial planning and analysis, risk management, tax and treasury as well as overseeing the investor relations and communications/public relations functions. Since joining SQZ in August 2019, Teri has raised over $200M for the company through a $65 million private crossover round, an $81M IPO as well as a $60M secondary offering.
Before joining SQZ Biotech, Teri served as Sr. Vice President of Investor Relations and Global Communications at Merck, a global pharmaceutical company. In this role, Teri led internal and external communications efforts globally, including corporate and financial media relations, product communications, public affairs and employee communications as well as its investor relations and investment community interactions. Prior to Merck, Teri was vice president, Investor Relations for IMAX Corporation, where she reshaped the entertainment company's investor strategy, helping to convert its investor base from predominantly short-term hedge funds to long-term institutional investors and helping the company go public in China with an IPO on the Hong Kong Exchange. Teri also spent over a decade at Bristol-Myers Squibb in a variety of roles of increasing responsibility across Strategy, Treasury and Investor Relations.
Teri started her career as a marine biologist and worked at Sea World of San Diego for several years before making a transition into business.
Teri holds an MBA from the University of California at Irvine and Bachelor of Science degree in Biology from the University of Victoria, B.C. Canada.